RecruitingNCT07274072

Hospital at Home Versus Inpatient Care: Costs and Effectiveness


Sponsor

Hospital at Home AG

Enrollment

200 participants

Start Date

Sep 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics. It bridges inpatient and outpatient care, working closely with hospitals, office-based physicians, home care services (Spitex), and therapy providers. There are two main pathways: Admission Avoidance: stable patients requiring hospitalization are admitted directly to HaH instead of an inpatient ward. Early Supported Discharge: patients treated in hospital are discharged earlier than usual and transferred to HaH. Evidence International studies show HaH to be safe and effective. Reviews report comparable mortality and rehospitalization, shorter hospital stays, and cost advantages. Admission avoidance is linked to trends toward lower mortality and costs. Research showed similar mortality but fewer rehospitalizations, longer treatment duration, and reduced risks of institutionalization, depression, and anxiety. HaH patients were older, with reduced daily living activities, yet care costs were on average USD 5,054 lower than inpatient care. In Switzerland, the mean hospital stay in 2019 was 8 days (acute somatic: 5.2; psychiatry: 33.5). Study Hypotheses HaH can be delivered at equal or lower cost than regular hospitalization. HaH care is safe, with few complications, and yields high patient satisfaction. Study Objective To demonstrate that hospital-equivalent home treatment of acutely ill patients is effective, appropriate, cost-efficient (according to Swiss WZW criteria), safe, and associated with high satisfaction and low complication rates compared with inpatient care. Endpoints Primary: Costs - HaH vs. inpatient care at Hirslanden Clinic, using REKOLE® cost accounting. Secondary: Mortality, therapy type, monitoring, diagnostics, rehospitalization, complications, satisfaction, patient-reported outcomes, length of stay, referrals to nursing homes, follow-up after discharge, ED visits, rehabilitation referrals, and home care type.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Inpatients in the hospital or patients in Hospital at Home care
  • Age ≥ 18 years
  • Admission due to a typical Hospital at Home diagnosis (mild to moderate inflammatory and infectious diseases of the lungs, urinary tract, gastrointestinal tract, heart, and skin; exacerbated chronic obstructive pulmonary disease; exacerbation of chronic heart failure; wounds; bleeding/anemia; dehydration; deterioration of general condition in multimorbid patients; infection-related complications in oncological patients; psychiatric problems including delirium; metabolic or autoimmune diseases; orthopedic patients; pain exacerbations of any cause; palliative patients up to and including terminal situations)
  • Patients without severe cognitive impairment or dysfunction who are capable of providing informed consent and/or completing the questionnaire
  • Patients with sufficient proficiency in written and spoken German and/or English

Exclusion Criteria2

  • Inpatient admission for other reasons
  • Refusal to provide informed consent

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hospital at Home AG

Zollikon, Canton of Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07274072


Related Trials